LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 50

Search options

  1. Article ; Online: Emerging effects of tryptophan pathway metabolites and intestinal microbiota on metabolism and intestinal function.

    Hyland, Niall P / Cavanaugh, Cassandre R / Hornby, Pamela J

    Amino acids

    2022  Volume 54, Issue 1, Page(s) 57–70

    Abstract: The metabolism of dietary tryptophan occurs locally in the gut primarily via host enzymes, with ~ 5% metabolized by gut microbes. Three major tryptophan metabolic pathways are serotonin (beyond the scope of this review), indole, kynurenine and related ... ...

    Abstract The metabolism of dietary tryptophan occurs locally in the gut primarily via host enzymes, with ~ 5% metabolized by gut microbes. Three major tryptophan metabolic pathways are serotonin (beyond the scope of this review), indole, kynurenine and related derivatives. We introduce the gut microbiome, dietary tryptophan and the potential interplay of host and bacterial enzymes in tryptophan metabolism. Examples of bacterial transformation to indole and its derivative indole-3 propionic acid demonstrate associations with human metabolic disease and gut permeability, although causality remains to be determined. This review will focus on less well-known data, suggestive of local generation and functional significance in the gut, where kynurenine is converted to kynurenic acid and xanthurenic acid via enzymatic action present in both host and bacteria. Our functional data demonstrate a limited effect on intestinal epithelial cell monolayer permeability and on healthy mouse ileum. Other data suggest a modulatory effect on the microbiome, potentially in pathophysiology. Supportive of this, we found that the expression of mRNA for three kynurenine pathway enzymes were increased in colon from high-fat-fed mice, suggesting that this host pathway is perturbed in metabolic disease. These data, along with that from bacterial genomic analysis and germ-free mice, confirms expression and functional machinery of enzymes in this pathway. Therefore, the host and microbiota may play a significant dual role in either the production or regulation of these kynurenine metabolites which, in turn, can influence both host and microbiome, especially in the context of obesity and intestinal permeability.
    MeSH term(s) Animals ; Gastrointestinal Microbiome/physiology ; Intestines ; Kynurenine/metabolism ; Mice ; Obesity/metabolism ; Tryptophan/metabolism
    Chemical Substances Kynurenine (343-65-7) ; Tryptophan (8DUH1N11BX)
    Language English
    Publishing date 2022-01-17
    Publishing country Austria
    Document type Journal Article ; Review
    ZDB-ID 1121341-3
    ISSN 1438-2199 ; 0939-4451
    ISSN (online) 1438-2199
    ISSN 0939-4451
    DOI 10.1007/s00726-022-03123-x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Drug discovery approaches to irritable bowel syndrome.

    Hornby, Pamela J

    Expert opinion on drug discovery

    2015  Volume 10, Issue 8, Page(s) 809–824

    Abstract: Introduction: Irritable bowel syndrome (IBS) is defined by symptoms of abdominal pain and altered bowel habits without detectable organic disease. Antidepressants and serotonin receptor modulators are used to treat IBS, but rare serious adverse events ... ...

    Abstract Introduction: Irritable bowel syndrome (IBS) is defined by symptoms of abdominal pain and altered bowel habits without detectable organic disease. Antidepressants and serotonin receptor modulators are used to treat IBS, but rare serious adverse events highlight the safety hurdle. Newer drugs with secretory and motility effects via local gut mechanisms have been successfully approved for IBS, often by registering first in a related, non-IBS condition to optimize dosing, formulation and therapeutic window.
    Areas covered: This review looks at approaches for novel IBS drug discovery. The underlying pathologies can be tackled locally from the 'outside-in' (intestinal lumen, mucosa and neuromuscular) to identify therapeutic targets. The article discusses the mechanisms associated with bile acid malabsorption, microbial dysbiosis, decreased intestinal barrier function, immune dysregulation, motility and visceral hypersensitivity.
    Expert opinion: Challenges for new drug discovery are the unknown mechanisms underlying IBS, making it difficult to predict clinically efficacious molecular targets, limited options for translational research and disease progression biomarkers. Drugs acting locally via multiple targets (e.g., eluxadoline [The U.S. Food and Drug Administration approved Viberzi (eluxadoline) for IBS-D on May 27th 2015], crofelemer) to validated mechanisms are proving successful with tolerable safety margins. Novel mechanisms, identified and optimized based on the emerging role of nutrient signaling, probiotics or microbial products, are promising. Therapeutic treatment earlier in disease progression may improve response and have longer term benefits.
    MeSH term(s) Abdominal Pain/drug therapy ; Abdominal Pain/etiology ; Animals ; Disease Progression ; Drug Design ; Drug Discovery ; Gastrointestinal Agents/adverse effects ; Gastrointestinal Agents/pharmacology ; Gastrointestinal Agents/therapeutic use ; Humans ; Irritable Bowel Syndrome/drug therapy ; Irritable Bowel Syndrome/physiopathology ; Molecular Targeted Therapy ; Probiotics/therapeutic use
    Chemical Substances Gastrointestinal Agents
    Language English
    Publishing date 2015
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2259618-5
    ISSN 1746-045X ; 1746-0441
    ISSN (online) 1746-045X
    ISSN 1746-0441
    DOI 10.1517/17460441.2015.1049528
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: The pharmacology and therapeutic applications of monoclonal antibodies.

    Castelli, María Sofía / McGonigle, Paul / Hornby, Pamela J

    Pharmacology research & perspectives

    2019  Volume 7, Issue 6, Page(s) e00535

    Abstract: Monoclonal antibodies (mAbs) have emerged as a major class of therapeutic agents on the market. To date, approximately 80 mAbs have been granted marketing approval. In 2018, 12 new mAbs were approved by the FDA, representing 20% of the total number of ... ...

    Abstract Monoclonal antibodies (mAbs) have emerged as a major class of therapeutic agents on the market. To date, approximately 80 mAbs have been granted marketing approval. In 2018, 12 new mAbs were approved by the FDA, representing 20% of the total number of approved drugs. The majority of mAb therapeutics are for oncological and immunological/infectious diseases, but these are expanding into other disease areas. Over 100 monoclonal antibodies are in development, and their unique features ensure that these will remain a part of the therapeutic pipeline. Thus, the therapeutic value and the elucidation of their pharmacological properties supporting clinical development of these large molecules are unquestioned. However, their utilization as pharmacological tools in academic laboratories has lagged behind their small molecule counterparts. Early therapeutic mAbs targeted soluble cytokines, but now that mAbs also target membrane-bound receptors and have increased circulating half-life, their pharmacology is more complex. The principles of pharmacology have enabled the development of high affinity, potent and selective small molecule therapeutics with reduced off-target effects and drug-drug interactions. This review will discuss how the same basic principles can be applied to mAbs, with some important differences. Monoclonal antibodies have several benefits, such as fewer off-target adverse effects, fewer drug-drug interactions, higher specificity, and potentially increased efficacy through targeted therapy. Modifications to decrease the immunogenicity and increase the efficacy are described, with examples of optimizing their pharmacokinetic properties and enabling oral bioavailability. Increased awareness of these advances may help to increase their use in exploratory research and further understand and characterize their pharmacological properties.
    MeSH term(s) Animals ; Antibodies, Monoclonal/chemistry ; Antibodies, Monoclonal/pharmacology ; Antibodies, Monoclonal/therapeutic use ; Biological Availability ; Disease Models, Animal ; Drug Evaluation, Preclinical ; Humans ; Immune System Diseases/drug therapy ; Immune System Diseases/immunology ; Infections/drug therapy ; Infections/immunology ; Molecular Targeted Therapy/methods ; Neoplasms/drug therapy ; Neoplasms/immunology ; Structure-Activity Relationship ; Tissue Distribution ; Treatment Outcome
    Chemical Substances Antibodies, Monoclonal
    Language English
    Publishing date 2019-12-11
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2740389-0
    ISSN 2052-1707 ; 2052-1707
    ISSN (online) 2052-1707
    ISSN 2052-1707
    DOI 10.1002/prp2.535
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Emerging effects of tryptophan pathway metabolites and intestinal microbiota on metabolism and intestinal function

    Hyland, Niall P. / Cavanaugh, Cassandre R. / Hornby, Pamela J.

    Amino acids. 2022 Jan., v. 54, no. 1

    2022  

    Abstract: The metabolism of dietary tryptophan occurs locally in the gut primarily via host enzymes, with ~ 5% metabolized by gut microbes. Three major tryptophan metabolic pathways are serotonin (beyond the scope of this review), indole, kynurenine and related ... ...

    Abstract The metabolism of dietary tryptophan occurs locally in the gut primarily via host enzymes, with ~ 5% metabolized by gut microbes. Three major tryptophan metabolic pathways are serotonin (beyond the scope of this review), indole, kynurenine and related derivatives. We introduce the gut microbiome, dietary tryptophan and the potential interplay of host and bacterial enzymes in tryptophan metabolism. Examples of bacterial transformation to indole and its derivative indole-3 propionic acid demonstrate associations with human metabolic disease and gut permeability, although causality remains to be determined. This review will focus on less well-known data, suggestive of local generation and functional significance in the gut, where kynurenine is converted to kynurenic acid and xanthurenic acid via enzymatic action present in both host and bacteria. Our functional data demonstrate a limited effect on intestinal epithelial cell monolayer permeability and on healthy mouse ileum. Other data suggest a modulatory effect on the microbiome, potentially in pathophysiology. Supportive of this, we found that the expression of mRNA for three kynurenine pathway enzymes were increased in colon from high-fat-fed mice, suggesting that this host pathway is perturbed in metabolic disease. These data, along with that from bacterial genomic analysis and germ-free mice, confirms expression and functional machinery of enzymes in this pathway. Therefore, the host and microbiota may play a significant dual role in either the production or regulation of these kynurenine metabolites which, in turn, can influence both host and microbiome, especially in the context of obesity and intestinal permeability.
    Keywords colon ; epithelial cells ; genomics ; humans ; ileum ; intestinal microorganisms ; kynurenine ; kynurenine pathway ; metabolic diseases ; metabolism ; metabolites ; mice ; microbiome ; obesity ; pathophysiology ; permeability ; propionic acid ; serotonin ; tryptophan ; xanthurenic acid
    Language English
    Dates of publication 2022-01
    Size p. 57-70.
    Publishing place Springer Vienna
    Document type Article
    Note Review
    ZDB-ID 1121341-3
    ISSN 1438-2199 ; 0939-4451
    ISSN (online) 1438-2199
    ISSN 0939-4451
    DOI 10.1007/s00726-022-03123-x
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

  5. Article ; Online: Intestinal SGLT1 in metabolic health and disease.

    Lehmann, Anders / Hornby, Pamela J

    American journal of physiology. Gastrointestinal and liver physiology

    2016  Volume 310, Issue 11, Page(s) G887–98

    Abstract: The Na(+)-glucose cotransporter 1 (SGLT1/SLC5A1) is predominantly expressed in the small intestine. It transports glucose and galactose across the apical membrane in a process driven by a Na(+) gradient created by Na(+)-K(+)-ATPase. SGLT2 is the major ... ...

    Abstract The Na(+)-glucose cotransporter 1 (SGLT1/SLC5A1) is predominantly expressed in the small intestine. It transports glucose and galactose across the apical membrane in a process driven by a Na(+) gradient created by Na(+)-K(+)-ATPase. SGLT2 is the major form found in the kidney, and SGLT2-selective inhibitors are a new class of treatment for type 2 diabetes mellitus (T2DM). Recent data from patients treated with dual SGLT1/2 inhibitors or SGLT2-selective drugs such as canagliflozin (SGLT1 IC50 = 663 nM) warrant evaluation of SGLT1 inhibition for T2DM. SGLT1 activity is highly dynamic, with modulation by multiple mechanisms to ensure maximal uptake of carbohydrates (CHOs). Intestinal SGLT1 inhibition lowers and delays the glucose excursion following CHO ingestion and augments glucagon-like peptide-1 (GLP-1) and peptide YY (PYY) secretion. The latter is likely due to increased glucose exposure of the colonic microbiota and formation of metabolites such as L cell secretagogues. GLP-1 and PYY secretion suppresses food intake, enhances the ileal brake, and has an incretin effect. An increase in colonic microbial production of propionate could contribute to intestinal gluconeogenesis and mediate positive metabolic effects. On the other hand, a threshold of SGLT1 inhibition that could lead to gastrointestinal intolerability is unclear. Altered Na(+) homeostasis and increased colonic CHO may result in diarrhea and adverse gastrointestinal effects. This review considers the potential mechanisms contributing to positive metabolic and negative intestinal effects. Compounds that inhibit SGLT1 must balance the modulation of these mechanisms to achieve therapeutic efficacy for metabolic diseases.
    MeSH term(s) Animals ; Enteroendocrine Cells/metabolism ; Gastrointestinal Motility ; Humans ; Intestinal Absorption ; Intestines/metabolism ; Metabolic Diseases/drug therapy ; Metabolic Diseases/genetics ; Metabolic Diseases/metabolism ; Metabolic Diseases/microbiology ; Sodium-Glucose Transporter 1/antagonists & inhibitors ; Sodium-Glucose Transporter 1/genetics ; Sodium-Glucose Transporter 1/metabolism
    Chemical Substances SLC5A1 protein, human ; Sodium-Glucose Transporter 1
    Language English
    Publishing date 2016-03-24
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 603840-2
    ISSN 1522-1547 ; 0193-1857
    ISSN (online) 1522-1547
    ISSN 0193-1857
    DOI 10.1152/ajpgi.00068.2016
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Design, synthesis and preclinical evaluation of bio-conjugated amylinomimetic peptides as long-acting amylin receptor agonists.

    Patch, Raymond J / Zhang, Rui / Edavettal, Suzanne / Macielag, Mark J / Eckardt, Annette J / Li, Jiali / Rives, Marie-Laure / Edwards, Wilson / Hinke, Simon A / Qiu, Xi / Jian, Wenying / Libiger, Ondrej / Zheng, Songmao / Jeyaseelan, Jey / Liang, Yin / Rangwala, Shamina M / Leonard, James N / Hornby, Pamela

    European journal of medicinal chemistry

    2022  Volume 236, Page(s) 114330

    Abstract: Pramlintide is an equipotent amylin analogue that reduces food intake and body weight in obese subjects and has been clinically approved as an adjunctive therapy for the treatment of adult diabetic patients. However, due to its extremely short half-life ... ...

    Abstract Pramlintide is an equipotent amylin analogue that reduces food intake and body weight in obese subjects and has been clinically approved as an adjunctive therapy for the treatment of adult diabetic patients. However, due to its extremely short half-life in vivo, a regimen of multiple daily administrations is required for achieving clinical effectiveness. Herein is described the development of prototypical long-acting pramlintide bioconjugates, in which pramlintide's disulfide-linked macrocycle was replaced by a cyclic thioether motif. This modification enabled stable chemical conjugation to a half-life extending antibody. In contrast to pramlintide (t
    MeSH term(s) Amylin Receptor Agonists/pharmacology ; Amylin Receptor Agonists/therapeutic use ; Amyloid ; Animals ; Body Weight ; Humans ; Hypoglycemic Agents/therapeutic use ; Islet Amyloid Polypeptide/pharmacology ; Mice ; Obesity/chemically induced ; Obesity/drug therapy
    Chemical Substances Amylin Receptor Agonists ; Amyloid ; Hypoglycemic Agents ; Islet Amyloid Polypeptide
    Language English
    Publishing date 2022-04-04
    Publishing country France
    Document type Journal Article
    ZDB-ID 188597-2
    ISSN 1768-3254 ; 0009-4374 ; 0223-5234
    ISSN (online) 1768-3254
    ISSN 0009-4374 ; 0223-5234
    DOI 10.1016/j.ejmech.2022.114330
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: The therapeutic potential of targeting the glucagon-like peptide-2 receptor in gastrointestinal disease.

    Hornby, Pamela J / Moore, Beverley A

    Expert opinion on therapeutic targets

    2011  Volume 15, Issue 5, Page(s) 637–646

    Abstract: Introduction: Glucagon-like peptide-2 (GLP-2) is a pleiotropic intestinotrophic hormone that enhances digestive and absorptive capacity by acting through a limited population of intestinal GLP-2 receptors. The development of protease-resistant analogs ... ...

    Abstract Introduction: Glucagon-like peptide-2 (GLP-2) is a pleiotropic intestinotrophic hormone that enhances digestive and absorptive capacity by acting through a limited population of intestinal GLP-2 receptors. The development of protease-resistant analogs or GLP-2/IgG fusion proteins confers a longer circulating half life than the native peptide. GLP-2 has garnered interest as a therapeutic most notably by reducing reliance on total parenteral nutrition in patients with short bowel syndrome.
    Areas covered: The clinical evidence for benefit in conditions requiring longer term treatment with GLP-2 receptor agonists, for example short bowel syndrome and inflammatory bowel disease. Benefits of short-term GLP-2 treatment are emerging in pre-clinical models, such as post-operative ileus, GI mucositis and conditions of altered intestinal permeability. The therapeutic utility of GLP-2 receptor agonists is limited by concern that it predisposes patients to gastrointestinal cancers, or their re-occurrence in cancer patients. This affects the types of diseases treated and, possibly, the duration of dosing.
    Expert opinion: GLP-2 is therapeutically attractive in diseases to enhance absorptive capacity, restore mucosal health and reduce inflammation. Long-term surveillance studies with a marketed therapeutic agent are needed to weigh the benefits of GLP-2 treatment against the potential effects on co-morbidities and increased risk of intestinal carcinogenesis.
    MeSH term(s) Animals ; Gastrointestinal Diseases/drug therapy ; Glucagon-Like Peptide 2/physiology ; Glucagon-Like Peptide-2 Receptor ; Humans ; Ileus/drug therapy ; Inflammatory Bowel Diseases/drug therapy ; Mucositis/drug therapy ; Receptors, Glucagon/agonists ; Receptors, Glucagon/physiology ; Short Bowel Syndrome/drug therapy
    Chemical Substances Glucagon-Like Peptide 2 ; Glucagon-Like Peptide-2 Receptor ; Receptors, Glucagon
    Language English
    Publishing date 2011-05
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2055208-7
    ISSN 1744-7631 ; 1472-8222
    ISSN (online) 1744-7631
    ISSN 1472-8222
    DOI 10.1517/14728222.2011.556620
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Intestinal serine protease inhibition increases FGF21 and improves metabolism in obese mice.

    Albarazanji, Kamal / Jennis, Matthew / Cavanaugh, Cassandre R / Lang, Wensheng / Singh, Bhanu / Lanter, James C / Lenhard, James M / Hornby, Pamela J

    American journal of physiology. Gastrointestinal and liver physiology

    2019  Volume 316, Issue 5, Page(s) G653–G667

    Abstract: Trypsin is the major serine protease responsible for intestinal protein digestion. An inhibitor, camostat (CS), reduced weight gain, hyperglycemia, and dyslipidemia in obese rats; however, the mechanisms for these are largely unknown. We reasoned that CS ...

    Abstract Trypsin is the major serine protease responsible for intestinal protein digestion. An inhibitor, camostat (CS), reduced weight gain, hyperglycemia, and dyslipidemia in obese rats; however, the mechanisms for these are largely unknown. We reasoned that CS creates an apparent dietary protein restriction, which is known to increase hepatic fibroblast growth factor 21 (FGF21). Therefore, metabolic responses to CS and a gut-restricted CS metabolite, FOY-251, were measured in mice. Food intake, body weight, blood glucose, branched-chain amino acids (LC/MS), hormone levels (ELISA), liver pathology (histology), and transcriptional changes (qRT-PCR) were measured in
    MeSH term(s) Adaptation, Physiological ; Animals ; Blood Glucose/metabolism ; Diet ; Fibroblast Growth Factors/blood ; Fibroblast Growth Factors/metabolism ; Gabexate/analogs & derivatives ; Gabexate/metabolism ; Guanidines/analysis ; Lipid Metabolism/physiology ; Liver/metabolism ; Mice ; Mice, Obese ; Nutritional Physiological Phenomena ; Obesity/metabolism ; Proteolysis ; Serine Proteinase Inhibitors/metabolism ; Transcription, Genetic/physiology
    Chemical Substances Blood Glucose ; Guanidines ; Serine Proteinase Inhibitors ; fibroblast growth factor 21 ; camostat (0FD207WKDU) ; Gabexate (4V7M9137X9) ; Fibroblast Growth Factors (62031-54-3) ; 4-(4-guanidinobenzoyloxy)phenylacetic acid (71079-09-9)
    Language English
    Publishing date 2019-03-28
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 603840-2
    ISSN 1522-1547 ; 0193-1857
    ISSN (online) 1522-1547
    ISSN 0193-1857
    DOI 10.1152/ajpgi.00404.2018
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Impaired glucose partitioning in primary myotubes from severely obese women with type 2 diabetes.

    Zou, Kai / Turner, Kristen / Zheng, Donghai / Hinkley, J Matthew / Kugler, Benjamin A / Hornby, Pamela J / Lenhard, James / Jones, Terry E / Pories, Walter J / Dohm, G Lynis / Houmard, Joseph A

    American journal of physiology. Cell physiology

    2020  Volume 319, Issue 6, Page(s) C1011–C1019

    Abstract: The purpose of this study was to determine whether intramyocellular glucose partitioning was altered in primary human myotubes derived from severely obese women with type 2 diabetes. Human skeletal muscle cells were obtained from lean nondiabetic and ... ...

    Abstract The purpose of this study was to determine whether intramyocellular glucose partitioning was altered in primary human myotubes derived from severely obese women with type 2 diabetes. Human skeletal muscle cells were obtained from lean nondiabetic and severely obese Caucasian females with type 2 diabetes [body mass index (BMI): 23.6 ± 2.6 vs. 48.8 ± 1.9 kg/m
    MeSH term(s) Adult ; Case-Control Studies ; Diabetes Mellitus, Type 2/metabolism ; Female ; Glucose/metabolism ; Glycogen/metabolism ; Glycolysis/physiology ; Humans ; Insulin/metabolism ; Muscle Fibers, Skeletal/metabolism ; Muscle, Skeletal/metabolism ; Obesity/metabolism ; Oxidation-Reduction ; Women
    Chemical Substances Insulin ; Glycogen (9005-79-2) ; Glucose (IY9XDZ35W2)
    Language English
    Publishing date 2020-09-23
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 392098-7
    ISSN 1522-1563 ; 0363-6143
    ISSN (online) 1522-1563
    ISSN 0363-6143
    DOI 10.1152/ajpcell.00157.2020
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Age-related neurodegenerative changes and how they affect the gut.

    Wade, Paul R / Hornby, Pamela J

    Science of aging knowledge environment : SAGE KE

    2005  Volume 2005, Issue 12, Page(s) pe8

    Abstract: The enteric nervous system (ENS) is the division of the autonomic nervous system that regulates gastrointestinal (GI) function. Although large numbers of enteric neurons may be lost with age, the GI tract remains surprisingly functional. Exceptions to ... ...

    Abstract The enteric nervous system (ENS) is the division of the autonomic nervous system that regulates gastrointestinal (GI) function. Although large numbers of enteric neurons may be lost with age, the GI tract remains surprisingly functional. Exceptions to this generality include swallowing disorders and reduced colonic motility in the elderly. Evidence of age-related neurodegenerative changes in structure and function of the ENS is briefly reviewed in this Perspective.
    MeSH term(s) Aging/physiology ; Animals ; Caloric Restriction ; Cell Death ; Enteric Nervous System/physiology ; Gastrointestinal Tract/innervation ; Gastrointestinal Tract/physiology ; Humans ; Muscle, Smooth/physiology ; Neurodegenerative Diseases/complications ; Neurodegenerative Diseases/physiopathology ; Neurons/pathology ; Rats
    Language English
    Publishing date 2005-03-23
    Publishing country United States
    Document type Journal Article ; Review
    ISSN 1539-6150
    ISSN (online) 1539-6150
    DOI 10.1126/sageke.2005.12.pe8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top